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Abstract
Deregulation of chromatin modifiers, including DNA helicases, is emerging as one of the mechanisms underlying the
transformation of anaplastic lymphoma kinase negative (ALK−) anaplastic large cell lymphoma (ALCL). We recently
identified the DNA-helicase HELLS as central for proficient ALK−ALCL proliferation and progression. Here we assessed
in detail its function by performing RNA-sequencing profiling coupled with bioinformatic prediction to identify HELLS
targets and transcriptional cooperators. We demonstrated that HELLS, together with the transcription factor YY1,
contributes to an appropriate cytokinesis via the transcriptional regulation of genes involved in cleavage furrow
regulation. Binding target promoters, HELLS primes YY1 recruitment and transcriptional activation of cytoskeleton
genes including the small GTPases RhoA and RhoU and their effector kinase Pak2. Single or multiple knockdowns of
these genes reveal that RhoA and RhoU mediate HELLS effects on cell proliferation and cell division of ALK−ALCLs.
Collectively, our work demonstrates the transcriptional role of HELLS in orchestrating a complex transcriptional
program sustaining neoplastic features of ALK−ALCL.
Introduction
Anaplastic large cell lymphomas (ALCLs) are a group of
neoplasms arising from the transformation of mature T-
cell1. The presence of chromosomal rearrangements
involving the ALK gene stratifies ALCLs in ALK+ and
ALK− identifying two distinct diseases with different
clinical behavior and prognosis2–4. ALK− are known to be
the most aggressive subtype of ALCL and the life expec-
tancy of affected patients is significantly reduced by the
lack of effective therapies4–6. The molecular bases of
ALK−ALCLs remain largely unknown as a consequence
of the biological complexity of this disease and of its
relative rarity that reduces the possibility of extensive
profiling7–11. Understanding the mechanisms that
underline the development and evolution of ALK−ALCLs
is crucial to define the molecular vulnerabilities of these
lymphomas and to develop specific therapeutic strategies.
DNA helicases are a class of enzymes whose primary
function is to unpack DNA. Considered as molecular
motors, these proteins unwind the DNA exploiting ATP
hydrolysis, thus facilitating replication and transcrip-
tion12–14. For their importance in DNA maintenance,
repair, and chromosomal segregation, helicases are con-
sidered guardian of the genomic stability15,16. Thus, it is
not surprising that genetic or transcriptional alterations in
many members of this family have been linked to different
disease conditions including predisposition to cancer17–20.
Besides, the relevance of these enzymes in promoting
transcription initiation and cancer progression, has
recently started to emerge as essential mechanism to
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explain their contribution to cell biology17,21,22. In virtue
of their centrality in this fundamental mechanism, heli-
cases are currently counted among the most appealing
targets for cancer therapies.
We recently demonstrated that HELLS, a DNA helicase
of the SWI/SNF2 family, is required for proficient
ALK−ALCLs proliferation. We showed that HELLS is a
downstream target of STAT3 and that its expression is
controlled by the ALK−ALCLs specific lncRNA Black-
Mamba. Besides, we demonstrated that BlackMamba
interacts with HELLS driving its positioning on target
promoters, suggesting that the role of this helicase in this
tumor setting may rely on its transcriptional activity8.
In this work, we explored in detail the molecular
function of HELLS investigating the transcriptional pro-
gram through which this helicase supports ALK−ALCLs.
We provided evidence that HELLS coordinates the
expression of a program of genes involved in cytoskeleton
organization and cytokinesis thus orchestrating timing of
cell division. We also showed that YY1 is a central partner
of HELLS in supporting this program.
Materials and methods
Cell culture and treatments
The human ALK−ALCL cell line MAC2A was a kind
gift of Dr. Giorgio Inghirami. The human Breast
Implanted Associated (BIA)-ALCL cell line TLBR-2 was a
kind gift of Dr. Alain Epstein. Cell identity was deter-
mined yearly. All cell lines were genotyped and routinely
tested for Mycoplasma contamination. Cell lines were
cultured in RPMI-1640 medium (Gibco) supplemented
with 10% FBS at 37 °C in an atmosphere of 5% CO2.
TLBR-2 cells were supplemented with IL2 (20U/ml).
Doxycycline hyclate was purchased from Sigma and
dissolved in H2O.
Cell growth and cell division
For cell growth assays, cells were washed with
phosphate-buffered saline, seeded at 2.5×105 cells/ml and
treated with 100 nM doxycycline. Viable cells were
counted by trypan blue exclusion.
Plasmids and viral infections
pLKO Tet-On vectors expressing shRNAs against
HELLS and lncRNA BlackMamba were generated by
cloning synthetic double-stranded oligonucleotides into
pLKO Tet-On vector (Addgene #21915). Vectors were
packaged into lentiviral particles HEK 293T-cell line and
used for infection of low passages MAC2A or TLBR-2 at
multiplicity of infection. Cells were selected with 0.5 or
1 μg/ml of puromycin (MAC2A and TLBR-2 respectively)
for 3 days.
The list of shRNAs sequences is provided in Supple-
mentary Table 1.
siRNA transfection
MAC2A and TLBR-2 cells (1×10^6) were transfected
with 30 nM siRNA concentration for single KD. SiRNA
transfections were performed using the Cell Line
Nucleofector Kit SF and Amaxa 4D Nucleofector (pro-
gram DS-130 for TLBR-2, FI115 for MAC2A). Twenty-
four hours after transfection, cells were harvested and
plated 2.5 × 105 cells/ml. For siRNA scramble, we used a
Silencer Select negative control (Ambion, Life Technol-
ogies). For PAK2 and RHOA we used a Silencer Select
Validated siRNAs, ID:s10022 and ID:s759, respectively
(Ambion, Life Technologies). For RHOU we used two
different Silencer Selected Pre-designed siRNAs
ID:224502, ID: s33826 (Ambion, Life Technologies). For
YY1, we used a Silencer Select Validated siRNAs: ID:
s14958 (Ambion, Life Technologies)
RNA extraction and quantitative PCR (qRT-PCR)
Total RNA was extracted by TRIzol (Thermo Fisher
Scientific) according to the manufacture’s instructions.
One microgram of total RNA was retrotranscribed using
the iScript cDNA kit, (Biorad). The amplified transcript
level of each specific gene was normalized on CHMP2A
housekeeping. ΔΔCt quantification method was used for
RT-qPCR analyses. The list of primers used is provided in
Supplementary Table 2.
Western blot
Western blot analysis was performed using standard
techniques8.
The primary antibodies were: HELLS (Rabbit
mAb#7998, 1:1000 Cell Signaling Technology), γ PAK2 (E-
9 Mouse mAb sc-373740, 1:1000 Santa Cruz Biotechnol-
ogy, Inc), RHOA (26C4 Mouse mAb sc-418, 1:1000 Santa
Cruz Biotechnology, Inc), RHOU (Rabbit, PA5-69128,
1:500 Invitrogen), YY1 (Rabbit, D3D4Q, 1:1000, Cell Sig-
naling Technology), β-tubulin antibody (sc-23949, 1:100,
Santa Cruz Biotechnology, Inc) and GAPDH (Rabbit
mAb#2118, 1:2000, Cell Signaling Technology)
All secondary antibodies (rabbit and mouse) were HRP-
conjugated (GE Healthcare) and diluted 1:3000.
Densitometric analysis was performed using the ImageJ
software.
Immunofluorescence (IF)
Cells were spotted on glass slides using Cytospin
(Thermo Scientific), fixed with 4% paraformaldehyde for
10min and permeabilized with 0.1% Triton X-100 for
3 min. Dots were blocked in 1% PBS-BSA solution for
40min at room temperature and incubated with phalloi-
din (Alexa Fluor® 488, Thermo Fisher) for actin staining
for 50min. Dots were washed in PBS for three times and
nuclei were stained with DAPI. For microtubules staining
we used β-tubulin antibody (sc-23949, 1:100, Santa Cruz
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Biotechnology, Inc). Immunofluorescences were detected
with Nikon Eclipse (Ni) microscope using 60X.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described8. Chro-
matin was precipitated with antibodies against HELLS
(4ug, Rabbit Polyclonal, orb178580, Biorbyt), YY1
(D3D4Q, 1:100, Cell Signaling Technolgy), or IgG-isotype
control (#66362, Cell Signaling Technology). Each qRT-
PCR value was normalized over the appropriate input
control and reported in graphs as a relative fold on IgG.
The list of primers used is provided in Supplementary
Table 2.
Co-Immunoprecipitation (Co-IP)
Cells were collected, crosslinked with 1% formaldehyde
for 10min, treated with 1.25M glycine for 5 min and
resuspended in Buffer A (10mM HEPES pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5% NP-40) supplemented with
protease inhibitor for 8 min in ice. After centrifugation at
3000 rpm for 2 min, the supernatant was collected as the
cytoplasmic fraction and used as the quality control of the
experiment. The pellet was washed two times with BUF-
FER B (10 mM HEPES pH7.9, 1.5 mM MgCl2, 10 mM
KCl), centrifuged at 3000 rpm for 2 min. Nuclei were
resuspended in lysis buffer (50 mM Tris-HCl pH 7.4,
150mM NaCl, 1 mM EDTA, 1% Triton X-100) supple-
mented with protease inhibitor and kept for 1 h in rota-
tion at 4°C. Nuclei extracts were sonicated using a
Bioruptor® Pico sonicator (Diagenode) and centrifuged at
16,000 g for 10 min. Supernatant was kept and was
quantified with Bradford. For each experiment, 4 mg of
nuclei extracts was used for immunoprecipitation and
150ɥg was kept as input control. Precoating step was
performed using Protein A-Sepharose® CL-4B beads (GE
Healthcare, Sigma Aldrich), HELLS antibody (Rabbit
Polyclonal, orb178580, Biorbyt). Preclearing step was
performed using total nuclear lysate and Protein A-
Sepharose beads for aspecific removal for 1 h in rotation
at 4°C. After centrifugation at 500 g for 5 min, we com-
bined the beads from precoating and supernatant from
preclearing steps and kept in rotation overnight at 4°C.
After centrifugation of 500 g for 5 min, the supernatant
was discarded and washed four times with TBS 1X
(50 mM Tris-HCl pH 7.4, 150 mM NaCl). Laemmli
Sample Buffer 4x (Biorad) was added to the immuno-
precipitated and samples were boiled for 20min. Co-IP
was detected by western blot using the secondary anti-
body mouse anti-rabbit IgG HRP conjugate (L27A9)
(#5127, 1:2000, Cell Signaling Technology).
Library preparation and RNA-sequencing
RNA seq libraries were obtained starting from 500 ng of
total RNA following Illumina TruSeq Stranded TotalRNA
preparation protocol. Sequencing was performed using
Illumina NEXSeq high-output cartridge (double-stranded,
reads length 75bp-2 ×75).
A sequencing depth of at least 60 million reads for each
sample was guaranteed.
Sequencing quality was assessed using the FastQC
v0.11.8 software (www.bioinformatics.babraham.ac.uk/
projects/fastqc/), showing on average a Phred score per
base >34 in each sample. Raw sequences were then aligned
to the human reference transcriptome (GRCh38, Gencode
release 30) using STAR version 2.723 and gene abundances
were estimated with RSEM algorithm (v1.3.1)24. Differential
expression analysis was performed using DESeq2 R pack-
age25, considering a False Discovery Rate (FDR) of 10% and
excluding genes with low read counts. Heatmap repre-
sentation and unsupervised hierarchical clustering with a
complete linkage method were exploited to graphically
depict differentially expressed genes (FRD < 0.1).
Significant genes underwent enrichment analysis, per-
formed on Gene Ontology biological processes, KEGG
and Reactome pathways databases via enrichR package26,
using a significance threshold of 0.05 on p-value adjusted
by Benjamini–Hochberg correction for multiple testing.
Transcriptional factors motif enrichment
For transcriptional factor motif search, JASPAR 2020
and PROMO (version 3.0.2) software tools were used. A
motif similarity threshold of 80% and a dissimilarity level
of 15% were respectively applied for JASPAR 2020 and
PROMO prediction results.
Statistical analysis
Statistical analyses were performed using the GraphPad
Prism Software (GraphPad). Statistical significance was
determined using Student’s t test. Each experiment was
replicated multiple time (>3 up to 6).
Results
HELLS controls ALK−ALCL proliferation by transcriptionally
coordinating a panel of cytoskeleton related genes
involved in cytokinesis
To get insight into the transcriptional regulation of
HELLS, we performed an RNA-sequencing profiling in
TLBR-2 cells which represent the ALK−ALCL subtype
known as Breast Implanted Associated (BIA)-ALCL8,27.
We generated inducible HELLS knockdown (KD) lines
(TLBR-2 HELLSKD) using doxycycline (DOX)-inducible
shRNA. HELLS KD was assessed by WB and qRT-PCR
(Fig. 1A, B) and functionally validated by the reduction in
the expression of already described HELLS-downstream
targets28 (Supplementary Fig. 1A). After DOX induction,
the gene expression profile of TLBR-2 HELLSKD cells was
analyzed and compared to the one obtained from
untreated cells used as control. Transcriptional changes
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Fig. 1 HELLS transcriptionally controls cytokinesis. A Western blot shows HELLS expression in TLBR-2 HELLSKD cells after 48 h of doxycycline
(DOX) induction. GAPDH was used as housekeeping gene. B qRT-PCR analysis of HELLS expression in TLBR-2 HELLSKD cells after 48 h of doxycycline
induction. The values represent mean ± SEM (n= 3) *p < 0.05; **p < 0.01. C The heatmap depicts hierarchical clustering based on the 728
differentially expressed genes, whose read counts are Z-score normalized. Unsupervised hierarchical clustering was performed between DOX and
CTRL samples (as indicated by the colored bar on columns) with a complete linkage method. Color intensity for each gene shows Z-score values
ranging from red for upregulation and green for downregulation D Most significant enriched pathways (adjusted p-value<0.05) are represented
showing the number of DE genes mapped in each considered pathway. E The heatmap depicts validated significantly downregulated genes. Green
color bar shows fold difference on Log2 scale calculated between DOX and CTRL samples. Darker green represents the most downregulated genes.
Genes in red were selected for further validations. F Immunofluorescence images of TLBR-2 HELLSKD cells and MAC2A HELLSKD cells after 48 h of
doxycycline (DOX) induction. Cells were stained with DAPI, F-actin, and β-tubulin antibodies. The white scale bar represents 10 μm.
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observed after HELLSKD revealed 728 differentially
expressed genes. 413 were downregulated and 315 were
upregulated upon HELLSKD with a FDR < 0.1 (Fig. 1C).
Gene ontology analysis of HELLS-target genes revealed
the enrichment of several categories including cell cycle,
DNA damage, histone modification, and chromatin
organization. Noticeably, top scoring in this list, there
were multiple Rho GTPases and cytoskeleton related
categories, including cytoskeleton regulation by Rho
GTPases and Rho GTPases signaling (Fig. 1D, E). This
was particularly interesting since we previously reported
that the reduced cellular proliferation displayed by
ALK−ALCL upon HELLS loss is associated with defects in
cytokinesis and a marked increase in multi-nucleated cells
of which Rho-GTPases are major players8.
To give a phenotypic readout to these results, we eval-
uated the organization of cytoskeleton in T-cells29 per-
forming immunostaining for β-tubulin (as a principal
constituent of microtubules) and for F-actin upon
HELLSKD in TLBR-2 and in an additional cell line
representing the systemic ALK−ALCL subtype (MAC2A)
(Supplementary Fig. 1B, C). Although we did not observe
differences in the quantity of β-tubulin (Supplementary
Fig. 1D), a less organized localization of β-tubulin in the
midzone of central spindle was detected in HELLSKD cells
as compared to control cells (Fig. 1F). By contrast, we
observed a profound reorganization of the F-actin with a
reduced alignment and compaction in cleavage furrow
structure. This phenomenon resulted in an incomplete
actomyosin ring formation in HELLSKD cells as compared
to control cells (Fig. 1F), in agreement with the multi-
nucleated phenotype previously reported8.
Together, these results indicate that, in ALK−ALCL,
HELLS contributes to an appropriate cytokinesis via the
transcriptional control of genes involved in contractile
ring regulation.
HELLS controls cytokinesis by directly binding to target
gene promoters
Using RT-qPCR, we validated a representative set of
altered genes involved in cytoskeleton and cytokinesis
confirming the RNA-sequencing results and the effect of
HELLS KD on these processes (Fig. 2A, Supplementary
Fig. 2A). Since we showed that HELLS cooperates with
the lncRNA BlackMamba for transcriptional activity in
ALK−ALCL and concurs to the lncRNA BlackMamba
pro-oncogenic role in these cells8, we investigated whe-
ther lncRNA BlackMamba was involved in the HELLS-
dependent regulation of these genes. Taking advance of
the previously generated TLBR-2 and MAC2A Black-
MambaKD inducible cell lines8, we showed that silencing
of this lncRNA resulted in an important reduction of all
tested HELLS-target genes (Fig. 2B, Supplementary Fig.
2B, C) confirming the functional synergy between
BlackMamba and HELLS and further indicating the
cytoskeleton related genes as a central node of the tran-
scriptional program supported by this axis in ALK−ALCL.
To further investigate the direct role of HELLS in the
regulation of these genes, we performed ChIP experi-
ments to assess the binding of HELLS on their promoters.
We observed a significant and specific enrichment of
HELLS binding on 10 out of 11 promoter regions tested in
both MAC2A and TLBR-2 cells (Fig. 2C). These data
confirm that HELLS acts as a transcriptional activator of
these genes.
YY1 is a transcriptional partner of HELLS in ALK−ALCL
Little is still known on the transcriptional function of
helicases. Thus, to explore how HELLS controls the
expression of its target genes we searched for putative
transcriptional factors (TFs) able to cooperate with
HELLS in ALK−ALCL. A region spanning 500 bp around
the transcriptional starting site (TSS) of each HELLS-
target gene was selected (Fig. 3A). A prediction search for
TF binding sites enriched in these regions was performed
using JASPAR30 and PROMO31 tools. 607 TFs and 26 TFs
were significantly identified by JASPAR and PROMO,
respectively. Merge of these lists resulted in a final list of 9
top scoring TFs and HELLS potential co-factors (pre-
dicted to bind up to 90% of the promoters regions used in
this search): Yin Yang 1(YY1), Transcription Factor AP-2
Alpha (TFAP2A), Sp1 transcriptional factor (SP1),
Nuclear Factor 1C (NFIC), MYB Proto-Oncogene Tran-
scription Factor (MYB), Forkhead Box P3 (FOXP3), ETS
Proto-Oncogene 1 (ETS1), ETS Transcription Factor
ELK1 (ELK1) and E2F Transcription Factor 1(E2F1)
(Fig. 3B, C).
To validate this analysis, we first tested the basal
expression of each of these TFs in ALK−ALCL cell lines. 7
out of 9 (78%) TFs were expressed in all tested cell lines
even if with variable levels. By contrast, no expression was
observed for FOXP3 and SP1 (Fig. 3D).
Next, we investigated the potential interaction of these
factors with HELLS by co-immunoprecipitation experi-
ments in nuclear extracts. Among all the TFs investigated,
only YY1 was found to interact with HELLS in both
TLBR-2 and MAC2A cells (Fig. 3E), although the levels of
YY1 in MAC2A cells are significantly lower than in
TLBR2. To enforce the idea of cooperation between
HELLS and YY1, we performed ChIP assay to investigate
the binding of YY1 on the promoter regions of HELLS-
target genes both in MAC2A and TLBR-2 cell lines. We
showed that 80% of the tested promoter (9/11) were
simultaneously bound by both factors supporting the
hypothesis of a functional cooperation between these two
factors (Fig. 3F). To establish a hierarchy within their
relationship, we analyzed how HELLS KD affects YY1
binding on target promoters. Noticeably, YY1 was
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displaced by these regions in the absence of HELLS while
no perturbation of YY1 expression levels was detected
upon HELLS KD (Fig. 3F, Supplementary Fig. 3A) indi-
cating that HELLS is crucial in positioning YY1 on spe-
cific target genes in the context of ALK−ALCL.
YY1 cooperates with HELLS to foster the transcription of
cytokinesis-related genes
YY1 is an ubiquitous transcriptional factor known to
have a fundamental role in normal and cancer-related
processes32. Thus, to consolidate its role as HELLS
partner in the transcriptional program of ALK−ALCL, we
silenced YY1 with specific siRNA. WB analyses and qRT-
PCR confirmed the efficiency of the silencing (Fig. 4A, B).
Parallel analysis demonstrated that previously reported
YY1 target genes33–35 were coherently altered upon its
KD (Supplementary Fig. 3B, C). Proliferation analysis of
TLBR2 and MAC2A transfected with either siRNA
against YY1 or scramble oligos as control did not evidence
a significant effect on cell proliferation (Fig. 4C). However,
we observed a significant increase in the number of multi-
nucleated cells in YY1KD (Fig. 4D, E).
Fig. 2 HELLS binds target gene promoters. A qRT-PCR validation of significantly downregulated genes obtained from RNA-sequencing. White bars
represent the most significantly downregulated genes (FDR < 0.1) and gray bars represent less significant downregulated genes (FDR > 0.1) in TLBR-2
HELLSKD cells and MAC2A HELLSKD cells after 48 h of doxycycline (DOX) induction. Each data represent mean ± SEM (n= 3). Two-tailed t-test. *p <
0.05; **p < 0.01. B qRT-PCR validation of significantly downregulated genes obtained from RNA-sequencing. White bars represent the most
significantly downregulated genes (FDR < 0.1) and gray bars represent less significant downregulated genes (FDR > 0.1) in TLBR-2 BlackMambaKD cells
and MAC2A BlackMambaKD cells after 6 days of doxycycline (DOX) induction. Each data represent mean ± SEM (n= 3). Two-tailed t-test. *p < 0.05;
**p < 0.01. C ChIP qRT-PCR detection of HELLS antibody in a panel of target gene promoters in TLBR-2 and MAC2A.P4_BlackMamba and α-satellite
were used as positive and negative controls, respectively. The values represent the relative fold enrichment over IgG and are indicated as mean ±
SEM (n= 3). Two-tailed t-test. *p < 0.05; **p < 0.01.
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Fig. 3 HELLS interacts with the transcriptional factor YY1. A Schematic representation of CDC42SE2 genomic locus showing the position, the
level of transcription and the enrichment of H3K4me3 on its putative promoter. B The Venn diagram represents the intersection between
transcriptional factors (TFs) identified by JASPAR (n= 607) and PROMO (n= 26) TFs binding prediction tools. The intersection shows the number of
HELLS-predicted and common TFs (n= 9). C JASPAR and PROMO similarity scores are represented for top-ranked enriched transcription factors (TFs).
D qRT-PCR analysis of top scoring TFs in TLBR-2 and MAC2A cell lines. Each data represent mean ± SEM (n= 3). E Nuclear extract from TLBR-2 and
MAC2A cells were tested for the presence of a multi-protein complex. Co-immunoprecipitation experiments were performed to evaluate binding of
HELLS to YY1. Western blots are representative of two independent experiments. F ChIP qRT-PCR detection of YY1 in TLBR-2 HELLSKD and MAC2A
HELLSKD after 48 h of doxycycline (DOX) induction. KLF4 and α-satellite were used as positive and negative controls, respectively. The values represent
the fold enrichment over IgG (representative of three independent experiments).
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Fig. 4 YY1 cooperates with HELLS to regulate the multi-nucleated phenotype. A Western Blot shows the knockdown of YY1 36 h post-
nucleofection with a specific siRNA in TLBR-2 and MAC2A. GAPDH was used as housekeeping gene. B qRT-PCR analysis of YY1 expression after
siRNA in TLBR-2 and MAC2A cell lines (36 h post-nucleofection). Each data represent mean ± SEM (n= 3). Two-tailed t-test. **p < 0.01. C The
graph represents the relative growth curve of TLBR-2 and MAC2A 72 h post-nucleofection with YY1 specific siRNA. Data were normalized on
siRNA scramble values. Each data point represents the mean ± SEM (n= 3). Two-tailed t-test. D. The panels show the percentage of multi-
nucleated cells in at least 500 cells stained with β-tubulin and F-actin antibodies (48 h post-nucleofection). Each data point represents the mean ±
SEM (n= 3). Two-tailed t-test. *p < 0.05; **p < 0.01. E Panels show representative immunofluorescences of TLBR-2 and MAC2A stained with DAPI,
F-actin, and β-tubulin antibodies 48 h post-nucleofection. The scale bar represents 10 μm. F qRT-PCR analysis of a panel of selected HELLS-target
genes in TLBR-2 and MAC2A 36 h post-nucleofection with specific YY1 siRNA. The values represent mean ± SEM (n= 3). Two-tailed t-test. *p <
0.05; **p < 0.01.
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Coherently, silencing of YY1 was associated with
repression of RHOU, PAK2, PLK1, AURKB, PITPNM1,
CDC42SE2, KLHL21, and KIF20A (Fig. 4F). This was in
line with a positive cooperation of YY1 and HELLS in the
regulation of cytokinesis genes and with the observed
increase in multi-nuclei. Intriguingly, YY1 did not affect
RHOA expression suggesting that other factors partici-
pate to HELLS transcriptional regulation of ALK−ALCLs.
The involvement of other transcriptional partners likely
accounts for the fact that YY1KD only partially recapitu-
lates HELLSKD phenotype.
Downstream effects of HELLS are mediated by multiple
Rho-GTPases and effectors
Rho-GTPases are a family of small GTPase proteins
involved in many aspects of intracellular actin dynamics
including cell division. During the cytokinesis, Rho-
GTPases trigger the initiation of the cleavage furrow
from which cytosol division begins36–39.
Rho-GTPases are also known for their role in the reg-
ulation of cell growth and proliferation and cytoskeleton
rearrangements in T-lymphomas40. Thus, to consolidate
the relevance of the transcriptional program associated
with HELLS, we investigated the relevance of these genes
in ALK−ALCL. To this end, we knocked down the
expression of RhoA, RhoU, and Pak2 with specific siR-
NAs. Since Rho-GTPases are known to work in a highly
cooperative manner41–43, we also combined siRNAs to
simultaneously knockdown two or more of these proteins.
Figures 5A and 5B show the efficiency of the silencing at
the mRNA and protein level in both MAC2A and TLBR-2
cells.
We noticed that while RhoAKD or Pak2KD did not alter
the expression of the others, RhoU KD exerted a sig-
nificant effect on RhoA expression, suggesting a tight
interplay between these two proteins.
Morphologically, RhoAKD and RhoUKD led to the
increase in the percentage of multi-nucleated cells relative
to siRNA scramble. By contrast, no such effect was
observed for Pak2 silencing. This phenomenon slightly
increased when RhoAKD and RhoUKD were combined. On
the contrary, combined RhoUKD/Pak2KD and RhoAKD/
Pak2KD did not increase the percentage of multi-
nucleated cells relative to RhoUKD and RhoAKD, respec-
tively. Consistently, triple KD resulted in an induction of
multinuclei comparable to combined RhoAKD/RhoUKD or
RhoAKD (Fig. 5C). To assess if the multi-nucleated phe-
notype resulted from cytokinesis failure44, we quantified
cytokinetic cells by immunofluorescence using F-actin
and β-tubulin staining. A significant decrease in the per-
centage of total cytokinetic cells and a relative increase in
abnormal cytokinetic cells were observed in single and
combined RhoAKD/RhoUKD compared to siRNA scram-
ble (Fig. 5D).
Immunofluorescences showed that both RhoAKD and
RhoUKD affected β-tubulin organization at central spin-
dles or midbody structures. The proper F-actin organi-
zation at contractile ring was also dramatically affected
resulting in an abnormal formation of cleavage furrow
(Fig. 5E). As expected, combined RhoAKD and RhoUKD
resulted in a more pronounced phenotype close to the one
obtained with HELLSKD (Fig. 5E).
The analysis of cell proliferation was coherent with
these observations. Single silencing of RhoU and Pak2 did
not affect significantly cell growth while a significant
decrease in cell proliferation was observed in RhoAKD in
both cell models. Combined RhoUKD/RhoAKD resulted in
a cell proliferation reduction similarly to single RhoAKD
whereas combined RhoUKD/Pak2KD enhanced the effects
of single RhoUKD and Pak2KD but only in TLBR-2.
Notably, triple KD resulted in a significant decrease in cell
proliferation, but this reduction was similar to RhoAKD or
RhoUKD/Pak2KD (Fig. 5F). Collectively, these data
demonstrated that RhoA and RhoU mediate HELLS
effects on cell proliferation and cell division of
ALK−ALCLs and that RhoA has a prominent role in this
process.
Discussion
Aberrant expression of epigenetic modifiers fostering
the transcriptional program of neoplastic T-cells is
emerging as a common feature and potential vulnerability
of ALK− ALCLs45,46.
In line with this evidence, here we showed that the
DNA-helicase HELLS supports ALK−ALCL proliferation
by controlling a gene expression program that is func-
tional for the execution of cytokinesis and therefore for
proficient cell division (Fig. 6).
HELLS is a multifunctional protein proved to play,
among the others, critical roles in DNA methylation,
chromatin packaging, and development of lymphoid tis-
sue47. Known also as Lymphoid-specific helicase (Lsh)
HELLS is required for normal development and survival
of lymphoid and other tissues via chromatin organiza-
tion4849, promotion of DNA double-strand break
repair50,51 and chromatin accessibility modification52,53.
In cancer, HELLS is deregulated in several settings i.e.
gliomas54, retinoblastoma55,56, prostate28, breast carcino-
mas57,58, medulloblastoma59, leukemia60 where it pro-
motes cellular proliferation and stemness. A significant
part of HELLS activity in these processes is mediated by
its transcriptional function. The way through which
HELLS controls gene expression is still partially unde-
fined. Its interaction with epigenetic silencers including
G9a61 and DNMTs62 as well as with transcriptional fac-
tors like E2F328,56 and c-Myc54 has been described. Here,
we added an additional part of information showing that
in the specific context of ALK−ALCL, HELLS interacts
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and functionally cooperates with the transcription factor
YY1. We demonstrate that DNA binding motif for YY1 is
enriched within the HELLS binding sites and that these
two factors physically interact and co-occupy the same
regions at the level of target promoters to ensure tran-
scription of a large set of cytokinesis-related genes.
Fig. 5 (See legend on next page.)
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YY1 is an ubiquitously expressed transcriptional factor
with a fundamental role in embryogenesis, adult hema-
topoiesis, differentiation, replication, and cellular pro-
liferation32,63,64. YY1 ensures the proper completion of
mitosis and its knockdown leads to defects in cytokinesis
and accumulation of multi-nucleated cells65. YY1 is often
deregulated in hematopoietic malignancies where it con-
trols the survival and growth of neoplastic cells66,67.
Coherently, here we reported that in ALK−ALCL loss of
YY1 is associated with accumulation of multi-nucleated
cells likely attributable to incomplete cytokinesis.
The functional relationship between HELLS and YY1
has never been described before. Interestingly, we showed
that the loss of HELLS leads to YY1 displacement from
DNA. This seems to indicate that HELLS, by altering
chromatin accessibility, works by priming the binding of
specific transcription factors to target promoters therefore
regulating specific set of context specific genes.
By RNA-sequencing profiling we showed that a sig-
nificant part of the HELLS transcriptional program in
ALK−ALCL converges on the regulation of cytoskeleton
and cytokinesis. To the best of our knowledge this is the
first time that the transcriptional activity of HELLS is
linked to these biological processes.
Cytoskeleton is the structure responsible for cell shape
maintenance and organization. It also confers mechanical
support to every cellular process from proliferation and
division to cell migration, adhesion, and interaction with
the surrounding microenvironment.
Of note, recent genetic and molecular profiling studies
have unveiled a critical role of cytoskeleton during
transformation and progression of T-cells68,69. Although
we still lack of a definitive overall view of how cytoske-
leton change during lymphomagenesis, the emerging
picture suggests that the cytoskeleton transcends the
maintenance of cell morphology and polarity providing a
more complex support to T-cells in the response to
intrinsic and environmental clues.
Among HELLS-downstream effectors, we identified
several Rho-GTPases and their related proteins including
RhoA, RhoU, and Pak2. Single and combined KDs of
these proteins highlight that RhoA and RhoU are key
effectors of HELLS program controlling both cell pro-
liferation and cell division.
RhoA is a key player in T-cell processes70 and its
deregulation has emerged as a central issue of T-
lymphoma biology68,70–73. Coherently, our results
demonstrate that RhoA is a fundamental effector of
HELLS-dependent oncogenic program. At the transcrip-
tional level, RhoA results regulated by HELLS but not by
YY1 suggesting a more complex regulation of this Rho-
GTPase in this setting. Limited information are available
on the regulation of RhoA74, and given its centrality,
additionally studies are needed to better clarify this point.
As RhoU can mediate the effects of WNT and
STAT3 signaling pathways in regulating cell morphology,
cytoskeletal organization, and proliferation75,76, our data
(see figure on previous page)
Fig. 5 Rho-GTPases mediate HELLS-downstream effects. A qRT-PCR analysis of RhoA, RhoU and Pak2 expression after single or combined siRNAs
in TLBR-2 and MAC2A cell lines (36 h post-nucleofection). Each data represent mean ± SEM (n= 3). Two-tailed t-test. *p < 0.05, **p < 0.01. B Western
blots show knockdown of RhoA, RhoU, or Pak2 36 h post-nucleofection with specific siRNAs in TLBR-2 and MAC2A. GAPDH was used as
housekeeping gene. C The histograms show the percentage of multi-nucleated cells in at least 500 cells TLBR-2 and MAC2A stained with DAPI, F-
actin, and β-tubulin antibodies (48 h post-nucleofection). Cells were nucleofected with single and combined specific siRNAs against RhoA, RhoU, and
Pak2. Each data point represents the mean ± SEM (n= 3). Two-tailed t-test. *p < 0.05 and **p < 0.01 relative to siRNA scramble. # p < 0.05 relative to
RhoAKD, RhoUKD, or Pak2KD. D The histograms show the percentage of cytokinetic cells in at least 500 cells TLBR-2 and MAC2A stained with DAPI, F-
actin, and β-tubulin antibodies (48 h post-nucleofection). The term “abnormal” refers to cytokinetic cells with defects in cleavage furrow and/or
microtubules structures. Cells were nucleofected with single and combined specific siRNAs against RhoA and RhoU. Each data point represents the
mean ± SEM (n= 3). Two-tailed t-test. *p < 0.05 and **p < 0.01 relative to siRNA scramble. E Immunofluorescence of TLBR-2 and MAC2A nucleofected
with siRNA scramble and single and combined RhoA and RhoU siRNAs (48 h post-nucleofection). Cells were stained with DAPI, F-actin, and β-tubulin
antibodies. The scale bar represents 10 μm. F Relative growth curve of TLBR-2 and MAC2A nucleofected with siRNA scramble and single or combined
RhoA and RhoU and Pak2 siRNAs (72 h post-nucleofection). Each data were normalized to siRNA scramble and represent the mean ± SEM (n= 3).
Two-tailed t-test. *p < 0.05 and **p < 0.01 relative to siiRNA scramble. # p < 0.05 relative to RhoAKD, RhoUKD, or Pak2KD.
Fig. 6 Proposed molecular mechanism. Schematic representation
of HELLS role in the regulation of ALK−ALCLs cytokinesis-related
program (created with BioRender.com).
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provide a new layer of complexity demonstrating a new
role of RhoU in cytokinesis via the STAT3-BlackMamba-
HELLS axis.
The cooperative role of Rho-GTPases in the execution
of neoplastic program driven by HELLS is in agreement
with their fundamental role in the regulation of cell
proliferation, cell division, and actin polymerization in
cancer77.
Collectively, our data provide novel insights into the
mechanism sustaining the progression of ALK−ALCL via
the untapped role of HELLS as transcriptional regulator of
cytokinesis. Since HELLS is expressed in many tumors
and plays a relevant role in the transcription and genomic
stability of cancers, its pharmacological inhibition may
represent a promising therapeutic strategy in lymphomas
and in other human neoplasms.
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